IPH5201 plus Imfinzi in perioperative NSCLC looks better than some but not other historical studies.
ApexOnco Front Page
Recent articles
Daraxonrasib scores a plenary session late-breaker.
Data on the group’s lead project, the PD-1 x CTLA-4 bispecific vudalimab, are far from emphatic.
Early activity of JANX007 in prostate cancer sees Janux stock gain 190%.
Not long after starting phase 1, RMC-6236 could be in pivotal trials this year.
After living in the shadow of Arcus’s TIGIT project, casdatifan might soon come into its own.
An “optimised formulation” of bezuclastinib looks promising, but the safety question remains open.
Nearly two thirds of key oncology filings are expedited; and what about the ones that aren’t?